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Abstract
Aims To study prospectively the impact of initiating insulin glargine in suboptimally controlled insulin-naı̈ve patients with
Type 2 diabetes on health-related quality of life in relation to glycaemic control.
Methods Insulin-naı̈ve Dutch patients with Type 2 diabetes in suboptimal glycaemic control (HbA1c > 53 mmol ⁄ mol; 7%)
on maximum dose of oral glucose-lowering medications were included from 363 primary care practices (n = 911). Patients
started insulin glargine and were followed up for 6 months. At baseline (start insulin therapy), 3 and 6 months, HbA1c was
measured and patients completed self-report health-related quality of life measures, including emotional well-being (World
Health Organization-5 well-being index), fear of hypoglycaemia (Hypoglycaemia Fear Survey) and diabetes symptom distress
(Diabetes Symptom Checklist—revised). Data were analysed using generalized estimating equations analysis.
Results HbA1c (mmol ⁄ mol; %) decreased from 69  16; 8.5  1.7 to 60  11; 7.61.0 and 57  11; 7.3  1.0 at 3 and
6 months, respectively (P < 0.001). Pre-insulin BMI (kg ⁄ m2) was 30  5.7, which remained stable at 3 months (30  5.8) and
increased to 31  5.9 at 6 months (P = 0.004); no significant changes in self-reported symptomatic and severe hypoglycaemia
were observed, while nocturnal hypoglycaemia slightly decreased. The Hypoglycaemia Fear Survey score decreased from
14.6  16.2 to 12.1  15.2 and 10.8  14.4 at 3 and 6 months, respectively (P < 0.001). The Diabetes Symptom
Checklist—revised score decreased from 15  14 to 10  12 and 10  13 (P < 0.001), with most pronounced reductions in
hyperglycaemic symptoms and fatigue. The World Health Organization-5 score increased from 57  25.3 to 65  21.6 at
3-month follow-up and 67  21.8 at 6-month follow-up (P < 0.001).
Conclusions Results of this observational study demonstrate combined glycaemic and health-related quality of life benefits of
initiating insulin glargine in patients with Type 2 diabetes in routine primary care.
Diabet. Med. 28, 1096–1102 (2011)
Keywords emotional well-being, insulin glargine, insulin initiation, quality of life
Abbreviations DSC-r, Diabetes Symptom Checklist—revised; HFS-w, Hypoglycaemia Fear Survey—Worry subcale;
ITAS, Insulin Treatment Appraisal Scale
Introduction
There is general consensus as to the need of timely insulin
initiation in Type 2 diabetes [1], but both patients and physicians
have concerns about possible adverse effects on quality of life [2].
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Although there is no compelling evidence that initiation of
(intensive) insulin therapy does hamper quality of life [3],
changing to insulin therapy is often delayed [4].
Inpastyears, long-acting insulinanalogueshavebeen introduced
as an alternative to NPH (humane isophane) insulin [5]. Insulin
glargine has been shown to have a more prolonged, consistent
duration of action, without the pronounced post-injection peak
characteristic of NPH insulin [6,7]. Although no glycaemic benefit
in terms of HbA1c has been demonstrated compared with NPH
insulin, the risk of hypoglycaemia is lower with glargine compared
with NPH [8]. However, research into the effects of initiation
of glargine on health-related quality of life is sparse [7–9].
A recent review identified only four studies that examined the
effect of glargine on health-related quality of life [9]. The
included studies reported improvements in treatment
satisfaction, perceived health status and quality of life
following initiation of glargine. However, external validity of
these studies was limited because of small, selective samples and
the impact of insulin glargine on fear of hypoglycaemia has
received little attention [8].
Outcomes of the recently published large multinational Lantus
vs. Levemir Treat-To-Target (L2T3) trial, concerning patients
with Type 2 diabetes in secondary care, suboptimally controlled
on oral glucose-lowering medication, who were randomized to
either insulin glargine or insulin detemir and followed for
6 months. Positive trends were found on fear of hypoglycaemia,
diabetes symptom distress and emotional well-being, with no
significant differences between glargine and detemir [10].
However, whether these trends in health-related quality of life
following initiation of a long-acting insulin analogue hold true in
routine primary care needs to be tested.
This prospective observational study in routine primary care
aimed to extend our understanding of the impact of initiating
once-daily insulin glargine on health-related quality of life in




In the present analysis, data from the Study of the Psychological
Impact in Real care of Initiating insulin glargine Treatment
(SPIRIT)wereused, anobservational studyconducted inprimary
care between 2005 and 2009. In total, 363 general practitioners
consented to participate and invited eligible patients with Type 2
diabetes to participate in the study. Data were gathered on
patients who were advised to add insulin glargine to their
treatment by their general practitioner, in accordance with the
Practice Guideline Diabetes Mellitus Type 2 of the Dutch
College of General Practitioners, which states that insulin
treatment should be initiated after therapy with maximum
dose of two oral agents fails to achieve good glycaemic control
(HbA1c > 53 mmol ⁄ mol; 7%) [11]. Insulin glargine was thus
initiated as part of routine care, at the discretion of the treating
general practitioner, based on existing titration protocols. The
study did not interfere with clinical routine and included only
filling out a questionnaire booklet in the practice office at three
consecutive consultations that took approximately 15 min of the
patients’ time. Inclusion criteria were: clinical need to initiate
insulin glargine, in concordance with the Practice Guideline
Diabetes Mellitus Type 2 of the Dutch College of General
Practitioners, obtained informed consent and the ability to
complete questionnaires. In view of its observational and non-
invasive nature, this study was deemed not subject to the Dutch
Medical Research Involving Human Subjects Act.
In total, 1063 Caucasian patients agreed to participate, of
whom 43 appeared to be already using insulin and 109 appeared
not suboptimally controlled (HbA1c £ 53 mmol ⁄ mol; 7%).
These subgroups were excluded from the analysis, resulting
in a sample of n = 911 (Fig. 1). Almost all patients started
once-daily insulin glargine combined with oral glucose-lowering
medication (n = 766) based on reported co-medication after
insulin initiation by 97% of 789 physicians.
Measures
Demographic and clinical data were obtained by self-report,
including age, gender, weight, time since diagnosis, previous
medication use, hypoglycaemic episodes during the past
363 GP’s agreed to 
participate 
43 already used insulin
109 HbA1c ≤ 7% / 53
mmol/mol
152 patients excluded
151 (17%) patients dropped out 
(lost to follow-up) 
1063 patients consented 
and included  
911 patients included in 
baseline measurement 
650 patients at 6 month 
follow-up 
760 patients at 3 month 
follow-up 
110 (14%) patients dropped out 
(lost to follow-up) 
FIGURE 1 Study flow chart.
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3 months, diabetes-related complications and co-morbidities. At
baselineandduringfollow-upvisitsat3and6 months,HbA1cand
fasting blood glucose were retrieved from the medical chart by
hand. HbA1c values older than 3 months (n = 96 at baseline,
n = 9at3-monthfollow-upandn = 7at6-monthfollow-up)were
set tomissing.Physicianswereasked to report relevant changes in
the treatment regimen to the researchers, as well as any adverse
events. During the study, two adverse events occurred, possibly
related to glargine treatment; one patient had strong fluctuations





Diabetes symptom distress was measured using the widely
used revised version of the Diabetes Symptom Checklist (DSC-r),
that has been shown to have good psychometric properties [13].
The DSC-r consists of 34 items grouped into eight symptom
subscales: Hyperglycaemia, Hypoglycaemia, Cognitive distress,
Fatigue,Cardiovasculardistress,Neuropathicpain,Neuropathic
sensibility and Ophthalmologic function. Each item asks about
the presence of the symptom (yes ⁄ no) and, if present, the level of
bothersomeness on a 5-point Likert-type scale. Scores are then
transformedtoa0–100score toobtain theDSC-r total score.The
same transformation is applied to the DSC-r subscales.
General emotional well-being was assessed with the World
Health Organization (WHO)-5 wellbeing index [13], a validated
instrument. The WHO-5 includes five items pertaining to
positive mood (good spirits, relaxation), vitality (being active
and waking up fresh and rested) and general interests (being
interested in things). Item scores are summated to provide a total
score, transformed to a 0–100 scale, with lower scores indicating
poorer well-being. The WHO-5 has been found to have good
screening properties for depressed mood, using a cut-off score of
28 or lower [14].
Additionally, five items from the Insulin Treatment Appraisal
Scale (ITAS [15]) were included to capture negative attitudes
towards insulin therapy at baseline [‘taking insulin means my
diabetes has become much worse’, ‘taking insulin makes life less
flexible’, ‘I am afraid of injecting myself with a needle’, ‘insulin
causes weight gain’ and ‘taking insulin increases the risk of low
blood glucose levels (hypoglycaemia)’]. Each item was scored on
a 0–4 Likert scale (from ‘strongly disagree’ to ‘strongly agree’),
resulting in a 0–20 total score. Item scores of 3 and 4
(agree ⁄ strongly agree) were taken as confirming a negative
attitude and possibly reluctance to initiate insulin therapy.
In the present study, Cronbach’s alpha’s for the HFS-w, DSC-r
and WHO-5 were 0.91, 0.94 and 0.90, respectively, confirming
high internal consistency. Cronbach’s alpha of the five items
derived from the ITAS was satisfactory (0.72).
Statistical analyses
The primary outcome was change in health-related quality of
life, defined by HFS-w, DSC-r and WHO-5 from baseline (prior
to insulin therapy) to 3 and 6 months following insulin
initiation. This was assessed modelling time as an independent
dummy variable using generalized estimating equations analysis.
Secondary outcomes (3- and 6-month change in HbA1c, fasting
blood glucose, the number of symptomatic, nocturnal and severe
hypoglycaemic episodes during the past 3 months and weight)
were analysed in a similar manner. Variables with a right-
skewed distribution were transformed using the natural
logarithm. This was the case for HbA1c, the number of
symptomatic, nocturnal and severe hypoglycaemic episodes
during the past month, the HFS-w, the DSC-r total score and the
sub-dimensions of the DSC-r. Analyses were based on the
intention-to-treat principle; patients who withdrew from
glargine use (n = 99; 11%) were thus included in the analyses.
Reasons for withdrawal were not known for 49 patients. For the
remaining patients, most frequent reported reasons as noted by
the physicians were: insufficient effectiveness (n = 16), low
compliance (n = 14) and co-morbidity (n = 7). Logistic
regression analyses, with dropout (yes ⁄ no) as the dependent
variable and demographic data, glycaemic data and total scores
of the health-related quality of life measures revealed that
dropout was not selective.
Confounding and effect modification were tested for age,
educational level, time since diabetes diagnosis, BMI (kg ⁄ m2),
the number of diabetes-related complications, the number of
co-morbidities, intensification of diabetes therapy by other
means than insulin glargine and baseline values for both the
primary and the secondary outcomes. Observational studies run
a high risk of missing data, attributable to the naturalistic setting
and lack of monitoring. For the HFS, missing data was noted for
28% of the participants at the start to 50% at 6-month follow-
up. For the DSC-r, these percentages were 28 and 50%. For the
WHO-5, they were 18 and 43%. Multiple imputation was used
for missing data, as multiple imputation minimally alters
variance of data and thus gives best estimates of missing data
[16]. Imputation was performed using the ICE package for Stata
version 10.0 (StataCorp, College Station, TX, USA), resulting in
ten data sets. Analyses on these data sets were combined using
Rubin’s rules for multiple imputation [17]. P-values of < 0.05
were considered to be statistically significant. Analyses were
carried out using Stata version 10.0.
Results
Baseline patient characteristics of the study population and
changes in clinical outcomes over time are shown in Table 1.
Prior to initiating insulin glargine, patients received oral
glucose-lowering medication as mono [n = 149, 18% of
physicians who correctly reported co-medication before
glargine initiation (n = 839)], dual (n = 534, 63%) or triple
(n = 156, 19%) therapy. At initiation of insulin glargine
treatment, 389 patients [49% of physicians who correctly
reported co-medication after glargine initiation (n = 789)]
received combination therapy with one oral glucose-lowering
medication. This percentage decreased to 42% at 3-month
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follow-up and increased to 48% at 6-month follow-up. Forty-
sevenper cent of thepatients (n = 374) received dual oral therapy
in combination with glargine. This percentage decreased to 44%
at 3 months and 32% at 6 months. Three patients (< 1%)
received tripleoral therapyontop of insulin. Nopatients received
combination therapy with three oral agents at 3 and 6 months.
Twenty-three patients (3%) received mealtime insulin as
combination therapy. This percentage increased to 13 and
20% at 3 and 6 months, respectively.
Before insulin initiation, median HbA1c was 67 mmol ⁄ mol;
8.3% (25th percentile: 61 mmol ⁄ mol, 7.7%; 75th percentile:
67 mmol ⁄ mol, 9.2%; range: 54–181 mmol ⁄ mol, 7.1–18.7%),
confirming a need for therapy intensification and decreased to a
median (25th, 75th percentile) of 60 (53, 67) mmol ⁄ mol; 7.6
(7.0, 8.3)% and 56 (50, 63) mmol ⁄ mol; 7.3 (6.7, 7.9)% at 3 and
6 months, respectively (P < 0.001). Fasting blood glucose
showed a similar pattern, falling from 10.8 ( 3.3) mmol ⁄ l at
baseline to 7.7 ( 2.2) at 3-month follow-up and 7.4 ( 2.2) at
6-month follow-up (P < 0.001). Mean weight increased by
1.2  8.1 kg and mean BMI increased by 0.4  2.8 kg ⁄ m2
during the study period. Thirty-seven per cent of the patients
(n = 334) reported to have experienced ‡ 1 mild hypoglycaemic
episode in a 3-month period before initiating insulin. This
percentage did not significantly change at 3-month follow-up,
but increased to 44% (n = 397) at 6-month follow-up
(P = 0.042). Fourteen per cent (n = 128) had experienced one
or more nocturnal hypoglycaemic episode at baseline. This did
not significantly change at 3-month follow up, but increased to
18%(n = 166)at6-month follow-up (P = 0.016).Threeper cent
of the patients (n = 29) had experienced one or more severe
hypoglycaemic episode before insulin initiation. This did not
change at 3-month follow-up, but significantly increased to 6%
(n = 52; P = 0.029) at 6-month follow-up.
Mean score on the five items derived from the ITAS (insulin
perceptions) was 8.5  4.4. Highest mean score was found for
the item ‘taking insulin means my diabetes has become much
worse’ (2.2  1.3). Approximately a quarter of the patients
(26%) had a mean score of ‡ 12 at baseline, suggesting a negative
attitude towards insulin, while agreeing to start insulin therapy.
HFS-w scores (fear of hypoglycaemia) were low at baseline
(median 8, 25th percentile 2, 75th percentile 22), but
nevertheless decreased slightly to a median of 4 (25th percentile
0, 75th percentile 15) at 6-month follow-up (P = 0.001,
corrected for demographics and combination therapy) (Table 2).
A small proportion of the patients reported not to have
experienced any of the 34 DSC-r symptoms at baseline (5%).
This increased slightly at 3 and 6 months (9 and 13%,
respectively; p = 0.019). Six per cent of the population
reported no symptom distress at baseline. At 3 and 6 months,
this percentage was 10 and 11%, respectively (P < 0.001). As for
the different sub-domains of the DSC-r, most pronounced
reductions were observed for the domains Fatigue [from
median 25, 25th and 75th percentiles 6 and 50 to a median
score of 13, 25th and 75th percentiles 0 and 31 at 6 months
(P < 0.001)] and Hyperglycaemia [from a median of 13 (25th
and 75th percentiles 0 and 26) to 6 (0, 16, P < 0.001) at
6 months] (Table 2).
Mean WHO-5 (well-being) scores improved from 57  26 to
65  21 at 6-month follow-up (P < 0.001) (Table 2).
Correction for HbA1c in the analyses with the WHO-5 showed
no significant changes (data not shown).
Discussion
In this 6-month observational study conducted in multiple
primary care practices in the Netherlands, we found pronounced
positive psychological effects following initiation of once-daily
insulinglargine in insulin naı̈vepatients with Type 2 diabetes. An
overall fall in HbA1c to a median of 56 mmol ⁄ mol; 7.3% was
observed during the 6-month period, which is still above the
currently recommended goal of 53 mmol ⁄ mol; 7%. Yet, it could
be regarded a safe target, in view of recent findings from the
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
and Action in Diabetes and Vascular Disease (ADVANCE) trials
[18]. Furthermore, a significant improvement was observed on
all three health-related quality of life measures. Interestingly, and
in contrast to common belief [19], fear of hypoglycaemia did not
significantly increase after insulin initiation. This could be
explained by the stable profile of insulin glargine with a low
risk of nocturnal hypoglycaemic episodes.
For symptomatic hypoglycaemic events, a non-significant
downward trend was observed. In contrast, a statistically
significant increase in the number of severe hypoglycaemic
eventswasobserved.However, this increasewasvery small and it
can be argued whether it is clinically relevant. Interestingly, on
both the Hypoglycaemia DSC-r subdomain and the HFS-w, a
significant decrease was observed.
Although patients were in suboptimal control at baseline, the
number of reported symptoms, as well as symptom distress
(DSC-r), were overall rather low compared with previous studies
[20–22]. Nevertheless, both symptom frequency and symptom
distress further decreased following insulin initiation. Most
pronounced benefits were observed in the subdomains
Hyperglycaemia, Cognitive complaints, Fatigue, Cardiovas-
cular complaints and Ophthalmologic symptoms.
For the DSC-r and the HFS, a cut-off point for clinical
significance is not available. Thus, to further explore clinical
significance of the observed changes in the health-related quality
of life measures, effect sizes (Cohen’s d) were calculated based on
comparisonofbaselinewith6-monthvalues.Aneffectsizeof0.8is
consideredlarge,0.5moderateand0.2small.WefoundaCohen’s
d of –0.14 for the HFS-w, 0.39 for the WHO-5 and –0.34 for the
DSC-r total score. As to the DSC-r subdomains, an effect size of –
0.43was found forHyperglycaemia, –0.26 forHypoglycaemia, –
0.28 for Cognitive functioning, –0.41 for Fatigue, –0.17 for
Cardiovascular functioning and a Cohen’s d of –0.23 was found
for Ophthalmologic function. These positive changes following
insulin initiation are to be considered small to moderate. General
emotional wellbeing (WHO-5) significantly improved following
the start of insulin therapy. A mean improvement of 8 points was
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found, close to the levelof clinical significancedefinedasachange
of 10 points by the authors of the WHO-5 [13].
Several limitations of the studyneedtobe mentioned. The non-
randomizeddesigncanbeconsideredalimitingfactor,threatening
internal validity because of selection bias and the lack of a control
group. We have no information on those who refused to
participate, but our study was conducted in a large and
heterogeneous sample of primary care patients across different
regionsofthecountry.Thesocio-demographicandclinicalprofiles
ofthepatientsdonotseemdissimilartowhatisreportedintheL2T3
trial [10], where a similar recruitment strategy was employed.
We cannot exclude the possibility of a study effect. However,
patients were not participating in a clinical trial, but rather
received usual care, with no additional benefits or incentives.
Moreover, the actual glycaemic improvement achieved during
the study period clearly exceeds the commonly observed decrease
in HbA1c as a result of a Hawthorne effect [23] and is similar to
previously reported results from comparable studies with a
longer follow-up [24,25].
As with glycaemic control, the observed improvements in
health-related quality of life at 3 months was sustained at
6 months following insulin initiation. It would seem highly
unlikely that these changes are simply attributable to an
expectancy effect. In fact, it would seem more logical to assume
that the opposite has occurred, i.e. patients have experienced real
benefits and symptom relief following insulin initiation, despite
initial worries and negative attitudes towards insulin and having
toinjectonadailybasis[4].Indeed,justoveraquarter(26%)ofthe
patients scored high on the five insulin attitude items, indicating a
negativeappraisalofinsulintherapyatbaseline.Thispercentageis
in line with earlier reported findings [4]. Furthermore, we did not
havedataonwhetherpatientswere livingaloneornot,whichmay
be a possible effect modifier on the health-related quality of life
outcomes, especially hypoglycaemia fear.
Table 1 Description of baseline population characteristics and changes in clinical outcomes during the study period







Age 62  11




n, % lower educated* 503, 55%
BMI (kg ⁄ m2) 30  6 30  6 31  6 0.192 0.004 0.003
Weight (kg) 88  19 88  18 89  18 0.245 0.003 0.003
HbA1c (mmol ⁄ mol) 67 (61–77) 60 (53–67) 56 (50–63) < 0.001 < 0.001 < 0.001
HbA1c (%) 8.3 (7.7–9.2) 7.6 (7.0–8.3) 7.3 (6.7–7.9) < 0.001 < 0.001 < 0.001
Fasting blood glucose
(mmol ⁄ l)




Symptomatic 2.6  6.5 2.3  5.3 1.9  3.7 0.633 0.647 0.972
n, % 0 episodes 572 (63%) 524 (58%) 514 (56%) 0.054 0.698 0.042
n, % 1 episode 63 (7%) 88 (10%) 92 (10%)
n, % 2 episodes 52 (6%) 72 (8%) 87 (10%)
n, % 3 episodes 49 (5%) 52 (6%) 53 (6%)
n, % ‡4 episodes 175 (19%) 175 (19%) 165 (18%)
Nocturnal 0.6  2.6 0.6  2.7 0.6  2.2 0.947 0.445 0.497
n, % 0 episodes 783 (86%) 781 (86%) 746 (82%) 0.525 0.074 0.016
n, % 1 episode 35 (4%) 46 (5%) 80 (9%)
n, % 2 episodes 27 (3%) 40 (4%) 30 (3%)
n, % 3 episodes 17 (2%) 7 (1%) 18 (2%)
n, % ‡4 episodes 49 (5%) 37 (4%) 37 (4%)
Severe 0.05  0.3 0.05  0.3 0.08  0.4 0.742 0.199 0.031
n, % 0 episodes 882 (97%) 872 (96%) 860 (94%) 0.356 0.109 0.029
n, % 1 episode 14 (2%) 29 (3%) 27 (3%)
n, % ‡ 2 episodes 15 (2%) 10 (1%) 24 (3%)
Raw mean  sd are presented for variables with a normal distribution, raw median (25th–75th percentile) are presented for variables with a
right-skewed distribution and number and per cent of respondents are presented for dichotomous variables.
P-values are adjusted for age, educational level, diabetes duration, BMI, the number of diabetes-related complaints, the number of
co-morbidities, intensification or relief of diabetes therapy by means other than insulin glargine and baseline values.
*Primary education or lower general secondary education.
Based on self-report.
Calculation of P-values not possible because of lack of statistical power.
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As mentioned, the relatively large number of missing data is a
potential weakness of observational studies and the present study
isnoexception.However,weusedmultipleimputation,whichcan
beviewedasthemostrobustwayofdealingwithmissingdata[16].
In summary, the present study is the first large population-
based study to report on the improvement in glycaemic control
and health-related quality of life following initiation of insulin
glargine inpatientswithType 2diabetes suboptimally controlled
on oral therapy. Our findings strongly suggest that improvement
of glycaemic control contributed to the observed improvements
in well-being, in particular vitality and general mood,
corroborating earlier findings [26,27]. It would seem safe to
conclude that initiating insulin glargine in patients with Type 2
diabetes who are suboptimally controlled has a positive effect on
patients’ quality of life. Conveying this information to patients
and healthcare providers would seem important in combating
the generally observed delay of insulin therapy.
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Men 19 (4–44) 13 (0–31) 13 (0–29) < 0.001 0.143 0.001
Women 30 (9–56) 19 (6–38) 19 (0–33) < 0.001 0.049 < 0.001
Cardiovascular 6 (0–19) 6 (0–16) 6 (0–14) 0.007 0.985 0.022
Neuropathic pain 6 (0–17) 1 (0–13) 3 (0–14) 0.033 0.271 0.475
Neuropathic sensory 4 (0–17) 4 (0–14) 4 (0–16) 0.325 0.773 0.590
Ophthalmologic 5 (0–15) 1 (0–13) 3 (0–10) < 0.001 0.854 < 0.001
WHO-5 total score 57  26 63  21 65  21 < 0.001 0.003 < 0.001
Raw mean  sd are presented for variables with a normal distribution, raw median (25th–75th percentile) are presented for variables with a
right-skewed distribution.
P-values are adjusted for age, educational level, diabetes duration, BMI, the number of diabetes-related complaints, the number of
co-morbidities, intensification or relief of diabetes therapy by means other than insulin glargine and baseline values.
*Interaction for gender was found (P = 0.003), results are presented separately for men and women.
DSC-r, Diabetes Symptom Checklist—revised; HFS-w, Hypoglycaemia Fear Survey—Worry subscale; WHO-5, World Health Organization-5.
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